RU2015140611A - Коньюгат бензофуранона и индола или азаиндола, его получение и применения - Google Patents
Коньюгат бензофуранона и индола или азаиндола, его получение и применения Download PDFInfo
- Publication number
- RU2015140611A RU2015140611A RU2015140611A RU2015140611A RU2015140611A RU 2015140611 A RU2015140611 A RU 2015140611A RU 2015140611 A RU2015140611 A RU 2015140611A RU 2015140611 A RU2015140611 A RU 2015140611A RU 2015140611 A RU2015140611 A RU 2015140611A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- combinations
- pharmaceutically acceptable
- benzofuranone
- azaindole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310202029.3 | 2013-05-28 | ||
| CN201310202029.3A CN103333161B (zh) | 2013-05-28 | 2013-05-28 | 1’-氧代靛玉红的制备和用途 |
| PCT/CN2014/000525 WO2014190758A1 (zh) | 2013-05-28 | 2014-05-26 | 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015140611A true RU2015140611A (ru) | 2017-07-04 |
Family
ID=49241382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015140611A RU2015140611A (ru) | 2013-05-28 | 2014-05-26 | Коньюгат бензофуранона и индола или азаиндола, его получение и применения |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9868734B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3006442A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016519167A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160012984A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103333161B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014273751A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2912943A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015016217A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015140611A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014190758A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| CN108721279B (zh) * | 2017-04-19 | 2021-06-29 | 安尼根有限公司 | 包含5′-羟基-5-硝基-靛玉红-3′-肟作为活性成分的乳腺癌治疗剂 |
| CN106946760A (zh) * | 2017-04-28 | 2017-07-14 | 遵义医学院 | 靛玉红衍生物或药学上能接受的盐用于抗肿瘤药物及制备方法 |
| CN111233741B (zh) * | 2020-03-04 | 2021-04-16 | 大连理工大学 | 一种有机催化靛红自缩合制备异靛蓝类化合物的方法 |
| US20230174548A1 (en) * | 2020-03-19 | 2023-06-08 | Board Of Regents Of The University Of Nebraska | Symbiotic prodrugs for the treatment of cancer and other diseases |
| WO2022171265A1 (en) * | 2021-02-09 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Modulators of complex i |
| CN113072540B (zh) * | 2021-03-29 | 2023-07-14 | 贵州医科大学 | 一种靛玉红衍生的降解剂及其制备与应用 |
| WO2023090935A1 (ko) * | 2021-11-18 | 2023-05-25 | 애니젠 주식회사 | 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS609022B2 (ja) * | 1981-06-19 | 1985-03-07 | イスクラ産業株式会社 | インジルビン誘導体およびそれを含有する抗腫瘍剤 |
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| JP2002516851A (ja) * | 1998-05-29 | 2002-06-11 | ゲルハルト アイゼンブランド | サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用 |
| CN1324355A (zh) * | 1998-10-22 | 2001-11-28 | 西巴特殊化学品控股有限公司 | 氧代苯并呋喃亚基-二氢吲哚酮 |
| EA200101046A1 (ru) * | 1999-04-12 | 2002-04-25 | Герхард Айзенбранд | Производные индигоидных бис-индолов |
| WO2000061124A2 (en) * | 1999-04-12 | 2000-10-19 | Gerhard Eisenbrand | Use off cell membrane penetrating indigoid bisindole derivatives |
| DE10053474A1 (de) * | 2000-10-24 | 2002-05-02 | Schering Ag | Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung |
| DE10061162A1 (de) * | 2000-11-30 | 2002-07-11 | Schering Ag | Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung |
| DE10125763A1 (de) * | 2001-05-17 | 2002-11-28 | Schering Ag | Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| US20100098702A1 (en) * | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| ATE484514T1 (de) * | 2001-12-13 | 2010-10-15 | Natrogen Therapeutics Inc | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs |
| CN1199946C (zh) * | 2002-10-29 | 2005-05-04 | 无锡杰西医药科技有限公司 | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| JP5448455B2 (ja) * | 2005-12-23 | 2014-03-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク (セ エン エール エス) | 新規3’−,7−置換インジルビンおよびそれらの適用 |
| CN101023944A (zh) * | 2006-02-23 | 2007-08-29 | 黎明涛 | 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用 |
| CN101314584A (zh) * | 2007-05-28 | 2008-12-03 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | HGF/c-Met信号通道抑制剂及其制备方法和用途 |
| CN101074229B (zh) | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| EP2379549B1 (en) * | 2008-12-22 | 2016-09-21 | Eisenbrand, Gerhard | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| EP2199292A1 (en) * | 2008-12-22 | 2010-06-23 | Technische Universität Kaiserlautern | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| CN101492410B (zh) * | 2009-03-05 | 2011-06-22 | 上海交通大学 | 用于抗肿瘤药物的靛玉红类化合物 |
| CN101492448B (zh) * | 2009-03-05 | 2012-09-19 | 上海交通大学 | 用于抗肿瘤药物的7'-氮杂靛玉红类化合物 |
| CN101492465A (zh) * | 2009-03-05 | 2009-07-29 | 上海交通大学 | 用于抗肿瘤药物的7,7'-二氮杂靛玉红类化合物 |
| CN101704813B (zh) * | 2009-11-25 | 2011-11-16 | 上海交通大学 | 1′-硫代靛玉红类化合物、用途及其制备方法 |
| CN101747339B (zh) * | 2009-11-25 | 2012-04-25 | 上海交通大学 | 1′-硫代氮杂靛玉红类化合物、用途及其制备方法 |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| US9051306B2 (en) * | 2011-07-15 | 2015-06-09 | Nihon University | Indirubin derivative having highly selective cytotoxicity for malignant tumors |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| CN103627748B (zh) * | 2013-11-21 | 2016-03-30 | 华侨大学 | 一种靛玉红衍生物的制备方法 |
-
2013
- 2013-05-28 CN CN201310202029.3A patent/CN103333161B/zh not_active Expired - Fee Related
-
2014
- 2014-05-26 CN CN201480016601.XA patent/CN105189486B/zh not_active Expired - Fee Related
- 2014-05-26 KR KR1020157026851A patent/KR20160012984A/ko not_active Withdrawn
- 2014-05-26 CA CA2912943A patent/CA2912943A1/en not_active Abandoned
- 2014-05-26 WO PCT/CN2014/000525 patent/WO2014190758A1/zh not_active Ceased
- 2014-05-26 US US14/779,719 patent/US9868734B2/en not_active Expired - Fee Related
- 2014-05-26 JP JP2016515609A patent/JP2016519167A/ja active Pending
- 2014-05-26 AU AU2014273751A patent/AU2014273751A1/en not_active Abandoned
- 2014-05-26 MX MX2015016217A patent/MX2015016217A/es unknown
- 2014-05-26 EP EP14803761.7A patent/EP3006442A4/en not_active Withdrawn
- 2014-05-26 RU RU2015140611A patent/RU2015140611A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3006442A1 (en) | 2016-04-13 |
| CN103333161A (zh) | 2013-10-02 |
| MX2015016217A (es) | 2016-03-01 |
| AU2014273751A1 (en) | 2015-10-29 |
| US9868734B2 (en) | 2018-01-16 |
| EP3006442A4 (en) | 2017-03-08 |
| KR20160012984A (ko) | 2016-02-03 |
| CN105189486B (zh) | 2018-07-31 |
| CA2912943A1 (en) | 2014-12-04 |
| CN103333161B (zh) | 2015-09-30 |
| JP2016519167A (ja) | 2016-06-30 |
| CN105189486A (zh) | 2015-12-23 |
| WO2014190758A1 (zh) | 2014-12-04 |
| US20160185771A1 (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| JP5925771B2 (ja) | ナイアシン模倣体、およびその使用方法 | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| US9669003B2 (en) | Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs | |
| AU2012361581B2 (en) | Effect potentiator for antitumor agents | |
| US20130281396A1 (en) | Treatment of diseases by epigenetic regulation | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| JP2013529645A (ja) | ナイアシン模倣体、およびその使用方法 | |
| WO2015176539A1 (zh) | 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途 | |
| CN101690713B (zh) | 一种喹诺酮注射液的制备方法 | |
| KR102382771B1 (ko) | 증식성 질환을 위한 조합 치료 | |
| WO2014002922A1 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2015512447A5 (cg-RX-API-DMAC7.html) | ||
| WO2014047782A1 (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
| US20220008409A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
| JP2022501315A (ja) | 病的炎症の新しい医療 | |
| JP2018508495A (ja) | スニチニブのプロドラッグ及び医薬組成物 | |
| RU2634618C1 (ru) | Анальгезирующее средство | |
| WO2015144029A1 (zh) | 甲基丙烯酰基苯并咪唑酮衍生物及其抗肿瘤用途 | |
| JP2012520264A (ja) | 5‐フルオロウラシルと1,4‐ジヒドロピリジン誘導体の薬学的組合せ、および癌治療におけるその利用 | |
| CN103709177A (zh) | 利福霉素类沃尼妙林杂合抗生素及其制备方法 | |
| TWI730019B (zh) | 噻二唑衍生物類dpp-iv抑制劑的結晶及其用途 | |
| WO2024213057A1 (zh) | Lsd1抑制剂与药物联用治疗癌症的用途 | |
| WO2016197944A1 (zh) | 无标题 | |
| RU2588133C2 (ru) | Ниациновые миметики и способ их использования |